Transarterial @entity157 treatment: Barcelona clinic liver XXXX staging system.

@entity1 @entity5 @entity2857 @entity49 @entity1575 @entity157
@entity157 ( @entity157 ), the fifth most common @entity5 that predominantly occurs in @entity1575 @entity1 , requires staging systems to design treatments. The barcelona clinic liver @entity5 staging system (BCLC) is the most commonly used @entity157 management guideline. For BCLC stage B (intermediate @entity157 ), transarterial chemoembolization (TACE) is the standard treatment. Many studies support the use of TACE in early and advanced @entity157 @entity1 . For BCLC stage 0 (very early @entity157 ), TACE could be an alternative for @entity1 unsuitable for radiofrequency ablation (RFA) or hepatic resection. In @entity1 with BCLC stage A, TACE plus RFA provides better local @entity5 control than RFA alone. TACE can serve as bridge therapy for @entity1 awaiting liver transplantation. For @entity1 with BCLC B, TACE provides survival benefits compared with supportive care options. However, because of the substantial heterogeneity in the @entity1 population with this stage, a better @entity1 stratification system is needed to select the best candidates for TACE. @entity2857 represents the first line treatment in @entity1 with BCLC C stage @entity157 . @entity2857 plus TACE has shown a demonstrable effect in delaying @entity5 progression. Additionally, TACE plus radiotherapy has yielded better survival in @entity1 with @entity157 and @entity49 . Considering these observations together, TACE clearly has a critical role in the treatment of @entity157 as a stand-alone or combination therapy in each stage of @entity157 . Diverse treatment modalities should be used for @entity1 with @entity157 and a better @entity1 stratification system should be developed to select the best candidates for TACE.
